SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DaiS who wrote (19916)3/21/1999 11:54:00 AM
From: VLAD  Read Replies (1) of 23519
 
DaiS,

The link worked fine when I tried it. I copied it whole for you to read:






Södertälje, Sweden, March 16, 1999 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA OR JAPAN

ASTRA / ZENECA MERGER: AGREEMENT REACHED WITH FTC STAFF AND INITIAL OFFER PERIOD EXTENDED

Astra AB and Zeneca Group PLC announce that very significant progress has been made with regard to the U.S. competition approval process, which is the only remaining regulatory consent required to effect the proposed Merger between the two companies. In particular, agreement has now been reached with the Staff of the Bureau of Competition of the Federal Trade Commission (FTC) on the terms of a Consent Decree which relates to a narrow product area. The Consent Decree and related agreements are subject to the approval of the FTC Commissioners who are reviewing the matter.

Commenting on the agreement with the FTC Bureau, Dr. Håkan Mogren, President and Chief Executive of Astra and Sir David Barnes, Chief Executive of Zeneca said 'We are encouraged to have reached agreement as regards the terms of the Consent Decree with the FTC staff. With the earlier approval of the European Union regulatory authorities we are optimistic that we are now close to obtaining the required regulatory approvals to effect the Merger.'

Consistent with market practice and the need to keep the offers open until the FTC review is complete, the offers by Zeneca Group PLC for all the issued share capital of Astra AB have been extended from 3 p.m. (Stockholm time) (9.00 a.m. New York time) on 18th March 1999 until 3 p.m. (Stockholm time) (9.00 a.m. New York time) on Tuesday 30th March 1999.

Astra and Zeneca are optimistic that approval will be obtained from the FTC Commis-sioners within the extended offer period.

Due to the mechanics of the closing of the Merger in Sweden and the intervening holiday period, Astra and Zeneca anticipate that a further announcement regarding the level of acceptances of the Merger Offers will be made on or shortly after Tuesday 6th April 1999.

Dealings in the new AstraZeneca shares are expected to commence as soon as is practical following the declaration that the merger is wholly unconditional. Subject to confirmation from the FTSE Index Committee, it is anticipated that AstraZeneca will replace Zeneca in the FTSE100 and All-Share indices within 24 hours of the start of dealings in AstraZeneca shares.

It is expected that AstraZeneca shares will be included in the Affärs-världens General Index and the OMX-index the day after the first day of dealings in AstraZeneca shares.




Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext